News
Video
Author(s):
Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.
Dostarlimab Wins Full Approval in Canada for dMMR/MSI-H Endometrial Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
OncLive’s June Roundup of Key FDA Approvals in Oncology
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer
Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes